New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
14:51 EDTMDXGMiMedx addressed reimbursement fears on call, says Craig-Hallum
Craig-Hallum said MiMedx management outlined reimbursement scenarios for when the company no longer has pass-through status, calming the fears of some investors. Craig-Hallum also noted that the company raised the lower-end of its FY14 revenue guidance to $95M from $90M and that management said its meeting with the FDA about its micronized injectable products was both "productive and helpful." The firm reiterates its Buy rating and $10 price target on MiMedx.
News For MDXG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
08:06 EDTMDXGMiMedx reports abstracts to be presented at Desert Foot Conference
MiMedx Group announced that fourteen poster abstracts chronicling the company's dehydrated human amnion/chorion membrane allografts to be clinically effective and cost effective in the healing of chronic wounds, difficult lower extremity wounds that have failed prior wound treatment modalities, challenging surgical wounds, chronic neuropathic wounds, wounds threatening the loss of limbs, and other hard-to-heal wounds will be presented at the 11th Annual Desert Foot High Risk Diabetic Foot Conference in Phoenix, Arizona, beginning November 19, and concluding on November 21.
November 17, 2014
16:06 EDTMDXGMiMedx reports results of EpiFix vs. Apligraf comparative study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use